The KLOW peptide blend is a compounded prescription formulation that supplies four peptides in a single vial: BPC-157, a synthetic 15-amino-acid peptide studied mainly in tendon, ligament, and gastrointestinal injury models; TB-500, a synthetic peptide built around the actin-binding region of the protein thymosin beta-4; GHK-Cu, a copper-binding tripeptide that occurs naturally in human plasma; and KPV, a three-amino-acid fragment of alpha-melanocyte-stimulating hormone studied for inflammation control.
The four are combined for a structural reason. Tissue repair runs in overlapping phases — bleeding control, inflammation, new-tissue growth, and long remodeling — and each peptide in KLOW has been studied against a different part of that sequence. This article goes through the blend component by component: what each peptide is, what the research measured and in whom, why the four sit in one formulation, and where the evidence is thin.
What the KLOW peptide blend contains
KLOW contains four peptides in one vial: BPC-157 (a synthetic 15-amino-acid peptide derived from a human gastric-juice protein), TB-500 (a synthetic analogue of thymosin beta-4's actin-binding region), GHK-Cu (a copper-bound human tripeptide), and KPV (an anti-inflammatory fragment of alpha-MSH). A licensed U.S. compounding pharmacy prepares the blend on a provider's prescription.
| Peptide | What it is | What it's studied for | Evidence tier |
|---|---|---|---|
| BPC-157 | Synthetic 15-amino-acid partial sequence of a protective protein found in human gastric juice | Tendon, ligament, muscle, bone, and GI-tract injury models; blood-vessel formation | Extensive animal data; two small human pilots (largest: 12 patients) |
| TB-500 | Synthetic fragment/analogue reproducing thymosin beta-4's actin-binding segment (LKKTETQ, residues 17–23) | Cell migration and wound closure — research conducted mostly on natural thymosin beta-4 in animal models | Preclinical; essentially no published human data on TB-500 itself |
| GHK-Cu | Naturally occurring tripeptide (glycine-histidine-lysine) bound to a copper(II) ion, present in human plasma | Collagen, elastin, and glycosaminoglycan synthesis in skin and wound models | Strong cell and animal data; few clinical studies |
| KPV | Tripeptide (lysine-proline-valine), the C-terminal fragment of alpha-MSH | Inflammation control, mainly in intestinal-inflammation models | Preclinical (cell and mouse models) |
All four are available only as compounded formulations prescribed at a provider's discretion.
BPC-157: the supply-line signal
BPC-157 is a synthetic peptide of 15 amino acids whose sequence is a fragment of Body Protection Compound, a protein isolated from human gastric juice. In KLOW it is the supply-line component: most of its studied effects involve signaling that supports new blood-vessel growth and the movement and survival of repair cells.
In preclinical work, BPC-157 engages the VEGFR2 receptor and promotes nitric-oxide production through the Akt–eNOS pathway — signaling tied to angiogenesis, the formation of new blood vessels (2025 narrative review). In a rat tendon study, it increased fibroblast migration and spreading, improved cell survival under oxidative stress, and activated the FAK–paxillin pathway — without directly increasing cell proliferation. Across rat gastrointestinal injury models, it was effective whether given by injection, by mouth, or locally, without the carrier molecules that growth factors such as EGF and VEGF require. Pharmacokinetic data put its half-life at under 30 minutes, with liver metabolism and renal clearance.
Nearly all of this is animal and cell work; the human record is summarized below. For a fuller profile, see our guide to BPC-157 peptide therapy.
TB-500: the cell-migration peptide
TB-500 is a synthetic peptide that reproduces the actin-binding region of thymosin beta-4 — the segment LKKTETQ, residues 17–23 of the natural protein. It is a fragment/analogue, not the same molecule as thymosin beta-4, and the distinction matters when reading research: most published findings describe the full natural protein.
Thymosin beta-4 is the body's main G-actin-sequestering peptide, present in virtually all cells; by regulating actin — the internal scaffolding cells use to move — it enables fibroblasts, keratinocytes, and endothelial cells to migrate toward a wound (Goldstein 2005). In a 1999 study, topical thymosin beta-4 accelerated wound closure in a rodent full-thickness skin-wound model. The protein has also been studied in animal and early clinical research on heart injury, organ fibrosis, eye-surface disease, and colitis (2021 review). Those findings belong to thymosin beta-4; TB-500 itself has essentially no published human data.
In the blend, TB-500's studied role is mobilization — getting repair cells to the site. Our companion piece on TB-500 and injury recovery goes deeper.
GHK-Cu: the matrix remodeler
GHK-Cu is a naturally occurring tripeptide — glycine-histidine-lysine — bound to a copper(II) ion. It was isolated from human plasma by biochemist Loren Pickart in 1973, and circulating levels decline with age: roughly 200 ng/mL in human plasma around age 20 versus about 80 ng/mL by age 60, in Pickart's original measurement set.
In fibroblast culture and animal wound models, GHK-Cu increases synthesis of collagen, elastin, and glycosaminoglycans — the structural materials of skin and connective tissue — and in-vitro transcriptomic profiling suggests it up- or down-regulates roughly 30 percent of profiled human genes (Pickart & Margolina 2018). It also delivers copper, a cofactor for the enzymes that crosslink collagen. Its role in KLOW is matrix quality: not simply more collagen, but remodeling toward organized tissue rather than scar-like matrix.
The main caveat: a 2024 review of topical GHK products reports an absence of clinical studies despite decades of strong cell-level data. For the full profile, see What does GHK-Cu do?
KPV: the inflammation gatekeeper
KPV is the smallest component of the blend: a tripeptide — lysine-proline-valine — that forms the C-terminal fragment of alpha-melanocyte-stimulating hormone. It carries much of that hormone's anti-inflammatory signaling without its pigmentation activity, and it is the component that makes KLOW a four-peptide blend rather than a three-peptide one.
Its best-characterized mechanism comes from intestinal research: KPV is carried into intestinal epithelial and immune cells by the PepT1 transporter, where it inhibits the NF-κB and MAPK inflammatory cascades, and in mouse colitis models it reduced intestinal inflammation (Dalmasso 2008). A 2016 study extended the anti-inflammatory finding to a murine colitis-associated cancer model.
KPV's job in the blend is gatekeeping. Acute inflammation is a necessary phase of repair, but inflammation that persists stalls new-tissue growth and worsens scarring; KPV's studied effect is modulation — damping inflammatory signaling without shutting down immunity. Our companion article on KPV covers the compound on its own terms.
Why the four are combined
The rationale is coverage. Tissue repair proceeds through four overlapping phases — hemostasis (clotting), inflammation (clean-up and repair signaling), proliferation (new vessels, new matrix, new surface), and remodeling (reorganizing that matrix over months to years) — and each of KLOW's components has been studied against a different part of that arc.
A 2026 review in JAAOS Global Research & Reviews makes the mechanistic case for the trio at KLOW's core: BPC-157, TB-500, and GHK-Cu act through distinct but complementary pathways — angiogenesis, integrin-mediated extracellular-matrix remodeling, and fibroblast activation. KPV adds a fourth axis, inflammation control, through a mechanism (PepT1 uptake, NF-κB/MAPK inhibition) that none of the other three uses.
A building analogy is imperfect but useful. BPC-157 lays the supply lines, TB-500 moves the work crews to the site, GHK-Cu drafts and finishes the structure, and KPV keeps the demolition phase from running long.
One thing the rationale is not: proof of synergy. The same 2026 review notes a "current lack of clinical trials" for therapeutic peptides in orthopaedics, and no study has tested the four-peptide combination itself. KLOW is combined on mechanism, not on a trial of the mixture.
KLOW vs. Wolverine vs. GLOW
Promise's recovery blends nest inside one another. Wolverine is the two-peptide core — BPC-157 plus TB-500, signaling plus cell mobilization — and our Wolverine guide covers that pair in detail. GLOW adds GHK-Cu as a third component, tilting the blend toward skin and matrix remodeling; it is currently waitlist-only at Promise (GLOW product page). KLOW adds KPV on top of that, extending the blend into inflammation control.
The practical decision usually reduces to scope. A narrow musculoskeletal focus points toward the two-peptide blend; interest in the matrix-remodeling and inflammation axes alongside recovery points toward the four-peptide one. Which is appropriate — if either is — is a prescribing decision a provider makes against your health history, not a menu choice.
What the human evidence shows
Most of the evidence behind KLOW's components is preclinical — cell culture and animal models — and the human data that do exist are small. The plain summary, component by component:
- BPC-157 has the most human data, and it is thin. A 2025 systematic review in HSS Journal identified 544 articles and included 36 studies — 35 preclinical and one clinical. That one clinical entry is a retrospective series of intra-articular BPC-157 for chronic knee pain, in which 7 of 12 patients reported relief lasting more than six months. One further indexed pilot sits outside that review's orthopaedic scope — a 2024 study in interstitial cystitis. Animal toxicity testing has not reached a toxic dose (Seiwerth 2021). BPC-157 is also prohibited in professional sport under WADA rules — relevant if you compete in tested athletics.
- TB-500 itself has essentially no published human data. The wound-healing and organ-injury findings in the literature were produced with natural thymosin beta-4, mostly in animal models.
- GHK-Cu has decades of cell and animal data on collagen and matrix synthesis, but clinical studies of GHK-Cu products are scarce.
- KPV's anti-inflammatory record is preclinical: cell and mouse models, concentrated in intestinal inflammation.
Reviews across these compounds converge on the same conclusion — promising preclinical signals, few clinical trials. That is the evidence tier a KLOW prescription rests on, and a good provider will say so plainly.
Where KLOW fits in a recovery plan
As one input among several — never the first one. The variables with the strongest evidence behind recovery are unglamorous: adequate protein and micronutrients, sleep, a graded return to loading, and managing whatever is driving systemic inflammation. A peptide blend, whatever its mechanistic appeal, sits on top of those fundamentals rather than in place of them.
KLOW is a prescription product: a licensed provider reviews every request against your health history, and not everyone qualifies — the provider can and does decline when the blend is not a clinical fit. If what you have read here matches what you are weighing — a compounded, multi-mechanism formulation with strong preclinical work and limited human data — that conversation is the next step.
This article is for educational purposes only and is not medical advice. It does not diagnose, and it does not replace a conversation with a licensed healthcare provider about your own health, medications, and history.
by Julian Reyes, Health Writer